Month: May 2022

JAK inhibitors

The first JAK inhibitor, Xeljanz (Tofacitinib), was approved for use by the FDA for rheumatoid arthritis use in 2012. It was a breakthrough medication for RA as it was the first to offer a targeted drug in pill form